Back to Search
WESLEY FIGG, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1326743253Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
PMID 19167733·J Urol·2009
2-rct
The Pharm.D. investigator in clinical pharmacology: supply and demand.
PMID 19238658·Clin Pharmacol Ther·2008
8-other
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
PMID 17437439·BJU Int·2007
3-trial
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
PMID 16413236·Clin Pharmacol Ther·2006
8-other
Scientific collaboration results in higher citation rates of published articles.
PMID 16716129·Pharmacotherapy·2006
8-other
Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics.
PMID 16880730·Cancer Biol Ther·2006
8-other
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
PMID 15592675·World J Urol·2004
8-other
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
PMID 19451403·J Clin Pharmacol·2009
3-trial
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
PMID 19483467·Cancer Biol Ther·2009
7-preclinical
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
PMID 19549766·Clin Cancer Res·2009
8-other
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
PMID 19431146·Int J Cancer·2009
8-other
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
PMID 19228751·Clin Cancer Res·2009
3-trial
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
PMID 19235596·Cancer Invest·2009
3-trial
NCI designated cancer center funding not influenced by organizational structure.
PMID 19270497·Cancer Biol Ther·2009
8-other
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
PMID 19228742·Clin Cancer Res·2009
8-other
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
PMID 19589782·J Biol Chem·2009
8-other
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
PMID 19591692·J Exp Clin Cancer Res·2009
7-preclinical
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.
PMID 19433787·Proc Natl Acad Sci U S A·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12631 E 17TH AVE
AURORA, CO 80045 - Phone
- (303) 724-1784
Quick Facts
- NPI
- 1326743253
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile